Perspective
Nature Reviews Cancer 8, 309-316 (April 2008) | doi:10.1038/nrc2346
Opinion: Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Rakesh K. Jain1 About the author
Top of page
Abstract
The importance of multidisciplinary translational clinical trials is obvious; however, making them work is complex and challenging. Here I present an argument for designing and implementing multidisciplinary mechanistic trials and present the lessons our team at the Massachusetts General Hospital Cancer Center has learned from two such trials in cancer patients with locally advanced rectal carcinomas and recurrent glioblastomas.
Author affiliations
-
Rakesh K. Jain is at the Edwin L. Steele Laboratory for Tumour Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Cox-7, Boston, Massachusetts 02114, USA.
Email: jain@steele.mgh.harvard.edu